RM-MET / Metabolic and incretin signalling
Eloralintide
Also known as: LY3532226 · LY3841136
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Eloralintide, also identified as LY3532226, is an investigational selective amylin receptor agonist studied for weight management.
Evidence position
A published randomized phase 2 trial supports Grade B. The molecule remains investigational and is not interchangeable with pramlintide or cagrilintide.
What the record does not establish
Class membership and a matching name do not prove sequence, modification, strength, formulation or quality of outside material.
Sources
- 01Eloralintide compound recordPubChem
- Shows
- Registry identity, structure, formula and molecular properties
- Does not show
- A registry identity does not establish approval or lot quality
- 02Eloralintide 48-week randomized phase 2 trialPubMed
- Shows
- Multicenter randomized human efficacy and safety results
- Does not show
- Results apply to the protocol-defined investigational product and population
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Eloralintide
- CID
- 175663130
- Formula
- C201H319N49O65S2
- Mass
- 4526
PUBMED / FOUND RECORDS
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.Molecular metabolism / 2025 DecPMID 41109426 / DOI 10.1016/j.molmet.2025.102271
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.Lancet (London, England) / 2025 Dec 6PMID 41207310 / DOI 10.1016/S0140-6736(25)02155-5
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.Diabetes, obesity & metabolism / 2026 AprPMID 41559929 / DOI 10.1111/dom.70439
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabolism open / 2026 JunPMID 41948476 / DOI 10.1016/j.metop.2026.100463
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.Peptides / 2026 MarPMID 41747885 / DOI 10.1016/j.peptides.2026.171480
CLINICALTRIALS.GOV / FOUND RECORDS
- A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityCOMPLETED / PHASE1 / Eli Lilly and CompanyNCT06916065 / DIRECT intervention MATCH: Eloralintide
- A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightCOMPLETED / PHASE1 / Eli Lilly and CompanyNCT06916091 / DIRECT intervention MATCH: Eloralintide
- A Study of LY3532226 in Participants With Type 2 Diabetes MellitusCOMPLETED / PHASE1 / Eli Lilly and CompanyNCT05407961 / DIRECT intervention MATCH: LY3532226
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRECRUITING / PHASE2 / Eli Lilly and CompanyNCT06143956 / DIRECT intervention MATCH: Eloralintide
- A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightRECRUITING / PHASE3 / Eli Lilly and CompanyNCT07369011 / DIRECT intervention MATCH: Eloralintide